Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mCC Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Improving Cancer Family Caregivers' Knowledge and Communication About Care Options

NCT02616107
View directory record Official record
Conditions
Family Caregivers
Interventions
Managing Cancer Care: A Caregiver's Guide, Symptom Management Toolkit
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 110 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 18, 2026, 5:56 AM EDT
Recruiting Phase 3 Interventional

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

NCT07578116
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
59
States / cities
Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Phase 2 Interventional Results available

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

NCT02155647
View directory record Official record
Conditions
Carcinoma, Merkel Cell
Interventions
Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
14
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 18, 2026, 5:56 AM EDT
Recruiting Phase 4 Interventional

Hypertonic Saline in NCFB

NCT06242795
View directory record Official record
Conditions
Bronchiectasis, Non-cystic Fibrosis Bronchiectasis
Interventions
7% Hypertonic Saline via nebulization
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Not applicable Interventional Results available

Testing the Helpfulness of 2 Decision Aids for Prostate Cancer

NCT00432601
View directory record Official record
Conditions
Prostate Cancer
Interventions
type of decision aid
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Male only
Enrollment
1,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
San Francisco, California • Ann Arbor, Michigan • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Phase 1 Interventional

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

NCT00928330
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
GDC-0941, Trastuzumab, trastuzumab-MCC-DM1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 5:56 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

TDCS to Improve Motivation and Memory in Elderly (TIME)

NCT04268186
View directory record Official record
Conditions
Motivation
Interventions
Direct tDCS, Indirect tDCS, Personalized tDCS, Sham tDCS
Device
Lead sponsor
Northeastern University
Other
Eligibility
65 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 18, 2026, 5:56 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

NCT01793649
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Obstructive Pulmonary Disease
Interventions
GS-5737
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

NCT02950805
View directory record Official record
Conditions
Pulmonary/Respiratory Diseases
Interventions
Placebo, AZD5634
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Not applicable Interventional

Strength and Function Following Total Hip Arthroplasty

NCT01817010
View directory record Official record
Conditions
Total Hip Arthroplasty
Interventions
Multi-Component Rehabilitation (CMC), Control (CON)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Not applicable Interventional

Behavioral Activation + Occupational Therapy

NCT05600465
View directory record Official record
Conditions
Multiple Chronic Conditions, Disability Physical
Interventions
Behavioral Activation + Occupational Therapy, Enhanced Usual Care
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
60 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 5:56 AM EDT
Active, not recruiting Phase 2 Interventional

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT04266249
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
Drug · Procedure · Biological + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
999
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 18, 2026, 5:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Malnutrition Clinical Characteristics Validation and Staffing Optimization Study (MCC Study)

NCT03928548
View directory record Official record
Conditions
Malnutrition
Interventions
Not listed
Lead sponsor
Academy of Nutrition and Dietetics
Other
Eligibility
1 Month and older
Enrollment
887 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

NCT00829166
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab emtansine, Lapatinib, Capecitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
177
States / cities
Chandler, Arizona • Tucson, Arizona • Anaheim, California + 149 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 18, 2026, 5:56 AM EDT
Completed No phase listed Observational

Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)

NCT01909362
View directory record Official record
Conditions
Colorectal Neoplasms, Advanced Metastatic Colorectal Cancer
Interventions
Not listed
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Incl Greenville, SC and Tyler, TX, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 18, 2026, 5:56 AM EDT
Enrolling by invitation Phase 4 Interventional

Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome

NCT06306157
View directory record Official record
Conditions
Complex Regional Pain Syndrome, Chronic Pain, Causalgia, Complex Regional Pain Syndrome Type I, Complex Regional Pain Syndrome Type II
Interventions
Low dose naltrexone, Placebo sugar capsules
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Not applicable Interventional

Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis

NCT01792271
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis
Interventions
Inhaled 7% HS (NaCl) home treatment
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 18, 2026, 5:56 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

NCT03071406
View directory record Official record
Conditions
Merkel Cell Carcinoma, Skin Cancer
Interventions
Nivolumab, Ipilimumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 18, 2026, 5:56 AM EDT
No Longer Available No phase listed Expanded access

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

NCT01120561
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
trastuzumab-MCC-DM1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
15
States / cities
Highland, California • Stockton, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 18, 2026, 5:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mobile Food Record on Recall Effects

NCT05228171
View directory record Official record
Conditions
Healthy
Interventions
mCC app
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)

NCT01967719
View directory record Official record
Conditions
Smoking
Interventions
mTHS 2.2, mCC, NNS
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
22 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Not applicable Interventional Results available

Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD

NCT03935932
View directory record Official record
Conditions
COPD
Interventions
nasal delivery of heated and humidified air
Device
Lead sponsor
Frank C Sciurba
Other
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 18, 2026, 5:56 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

NCT03747484
View directory record Official record
Conditions
Other Skin
Interventions
Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab, Interferon Gamma-1b
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 18, 2026, 5:56 AM EDT
Completed Phase 2Phase 3 Interventional

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

NCT00406068
View directory record Official record
Conditions
Bladder Neoplasms
Interventions
Mycobacterial cell wall-DNA complex
Drug
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • San Diego, California • New Britain, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 18, 2026, 5:56 AM EDT